Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial
2009 (English)In: European Journal of Cancer, ISSN 0959-8049, Vol. 45, no 14, 2496-2502 p.Article in journal (Refereed) Published
Background: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. Patients and methods: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. Results: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p = 0.02). In subgroup analysis the risk reduction was most pronounced in patients less than40 years of age (HR 0.09, p = 0.02). A risk reduction was also seen in women 40-49 years of age or ≥50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. Conclusion: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women less than40 years of age. The effect of tamoxifen was not significantly dependent on time.
Place, publisher, year, edition, pages
2009. Vol. 45, no 14, 2496-2502 p.
Adjuvant tamoxifen; Breast cancer; Contralateral breast cancer; Hormone receptor status; Premenopausal; Randomised controlled trial
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-21241DOI: 10.1016/j.ejca.2009.05.022OAI: oai:DiVA.org:liu-21241DiVA: diva2:240990